---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-017656"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:23:21.445503+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics reports FY2024 net loss of $71.3M; briquilimab data positive

## Summary
- Cash and equivalents $71.6M at Dec 31, 2024; net loss $71.3M ($4.89 diluted EPS) for FY2024.
- BEACON study in CSU: multiple dosing regimens ≥120mg showed >25-point UAS7 improvement; Phase 2b expected H2 2025.
- SPOTLIGHT study in CIndU: 14 of 15 patients (93%) achieved clinical response; 83% complete response in 120mg cohort.
- First patient dosed in ETESIAN asthma study; initial data expected H2 2025.
- Open-label extension study commenced; initial data from ~30 patients expected mid-2025.

## SEC filing metadata
- accession: 0001213900-25-017656
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390025017656/0001213900-25-017656-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390025017656/ea0232349-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-017656
- JSON: https://secwatch.observer/filing/0001213900-25-017656.json
- Plain text: https://secwatch.observer/filing/0001213900-25-017656.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.